Core Viewpoint - Peijia Medical-B (09996) experienced a nearly 7% increase in stock price following the approval of its TaurusTrio™ transcatheter aortic valve (TAV) system by the National Medical Products Administration of China [1] Group 1: Company Developments - Peijia Medical announced the approval of its TaurusTrio™ TAV system's registration application on December 11 [1] - The TaurusTrio™ TAV system is developed and manufactured based on an exclusive license from JenaValve Technology, Inc. for the Trilogy™ transcatheter heart valve (THV) system [1] - The Trilogy™ THV system received CE mark certification in May 2021 and has been used in over 1,000 commercial surgeries in real-world clinical practice as of the announcement date [1] Group 2: Market Implications - The company anticipates that the successful launch of the TaurusTrio™ TAV system in China will provide a safe and effective treatment option for patients with severe aortic regurgitation (AR), addressing a significant unmet clinical need [1]
港股异动 | 沛嘉医疗-B(09996)涨近7% TaurusTrio经导管主动脉瓣系统中国正式获批